A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis
Phase 1/Phase 2
This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study
comparing 3 mg/kg of AIN457 to placebo. Subjects with a diagnosis of moderate to severe
stable plaque psoriasis will be randomized to receive either AIN457 or placebo. AIN457 or
placebo will be administered by single infusion at baseline and subjects will be observed
for up to 26 weeks following the infusion.
Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients
Phase 1/Phase 2
Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as a
single dose (intravenous infusion) in patients with active rheumatoid arthritis in
combination with a stable dose of methotrexate. And to compare efficacy on the dose groups.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.